1. LEVO-CTS
Trial design: Patients undergoing cardiac surgery with the use of cardiopulmonary bypass were randomized to infusion of levosimendan 0.2 µg/kg/min for 1 hour, then 0.1 µg/kg/min for 23 hours (n = 442) versus placebo infusion (n = 440).
Results
(p = 0.98)
Short-term death, MI, dialysis, or mechanical assist device: 24.5% of the levosimendan group versus 24.5% of the placebo group (p = 0.98)
Death or mechanical assist device: 13.1% of the levosimendan group versus 11.4% of the placebo group (p = 0.45)
Death at 30 days: 3.5% for levosimendan vs. 4.5% for placebo
24.5
24.5 %
Conclusions
Among patients with low LVEF undergoing cardiac surgery with cardiopulmonary bypass, levosimendan was not beneficial
Levosimendan did not improve either of the two coprimary endpoints compared with placebo
Levosimendan
Placebo
Mehta RH, et al. N Engl J Med 2017;Mar 19:[Epub]